Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer

METex14 skipping mutations occur in about 3–4% of lung adenocarcinoma patients and 1–2% of patients with other lung cancer histology. The MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) are established oncogenic drivers of NSCLC. A mutation that results in loss of exon 14...

Descripción completa

Detalles Bibliográficos
Autores principales: Drusbosky, Leylah M., Dawar, Richa, Rodriguez, Estelamari, Ikpeazu, Chukwuemeka V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381548/
https://www.ncbi.nlm.nih.gov/pubmed/34425853
http://dx.doi.org/10.1186/s13045-021-01138-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381548/
https://www.ncbi.nlm.nih.gov/pubmed/34425853
http://dx.doi.org/10.1186/s13045-021-01138-7

Ejemplares similares